The role of pharmacoepidemiology and pharmacoeconomics in promoting access and stimulating innovation.

abstract：:As part of the Single Technology Appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the manufacturer (AstraZeneca) of durvalumab (IMFINZITM) to submit evidence for the clinical and cost effectiveness of durvalumab for the treatment of patients with locally advanced, unresecta...

journal_title：PharmacoEconomics

authors： Witlox WJA,van Asselt ADI,Wolff R,Armstrong N,Worthy G,Chalker A,Buksnys T,Stirk L,Kleijnen J,Joore MA,Grimm SE

更新日期：2020-04-01 00:00:00

abstract：:Advanced controlled release (CR) dosage forms are relative newcomers to pharmaceutical markets, and few studies relate their efficacy, safety or compliance benefits to economic value. This literature review was undertaken to assess the cost effectiveness of CR dosage forms using such measures as purchase costs, total ...

journal_title：PharmacoEconomics

authors： Cramer MP,Saks SR

更新日期：1994-06-01 00:00:00

abstract：OBJECTIVE:The objective of this study was to estimate the per-patient-per-month (PPPM) costs of medications in the six Medicare Part D protected classes based on findings among Medicare and dual eligible beneficiaries with drug coverage before the enactment of the benefit. DESIGN:Data were from the Thomson Medstat Mar...

journal_title：PharmacoEconomics

authors： Mucha L,Masia NA,Axelsen KJ

更新日期：2006-01-01 00:00:00

abstract：OBJECTIVE:The objective of this study was to examine the cost effectiveness of fluvoxamine compared with tricyclic antidepressants (TCAs) in the treatment of patients with depressive episodes. DESIGN AND SETTING:A Markov process model was constructed to model the effectiveness, as measured by time without depression, ...

journal_title：PharmacoEconomics

authors： Nuijten M,Hadjadjeba L,Evans C,van den Berg J

更新日期：1998-10-01 00:00:00

abstract：OBJECTIVES:Patients with chronic kidney disease (CKD) are commonly treated with renin-angiotensin-aldosterone system inhibitors (RAASi) in order to delay progression of renal disease. However, research has shown that RAASi in CKD patients increases hyperkalaemia (HK) prevalence, which leads to RAASi discontinuation or ...

journal_title：PharmacoEconomics

authors： Widén J,Ivarsson M,Schalin L,Vrouchou P,Schwenkglenks M,Heimbürger O,Ademi Z,Sutherland CS

更新日期：2020-07-01 00:00:00

abstract：:Lung cancer remains the leading cause of cancer-related death and economic burden worldwide. Despite the heavy toll of lung cancer, multiple new advances have improved patient outcomes, largely through precision medicine and targeted therapy. The associated rising economic burden however may impact the uptake of novel...

journal_title：PharmacoEconomics

authors： Albaba H,Lim C,Leighl NB

更新日期：2017-12-01 00:00:00

abstract：BACKGROUND:The recently completed ALEX trial demonstrated that alectinib improved progression-free survival, and delayed time to central nervous system progression compared with crizotinib in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer. However, the long-term clinical and economic impac...

journal_title：PharmacoEconomics

authors： Carlson JJ,Suh K,Orfanos P,Wong W

更新日期：2018-04-01 00:00:00

abstract：OBJECTIVE:A cost-effectiveness analysis of oral capecitabine versus intravenous bolus 5-fluorouracil/l-leucovorin (FU/LV) as adjuvant therapy in patients with stage 3 colon cancer was performed from a Japanese healthcare payer perspective. METHODS:Adjuvant therapy comprised 24 weeks of treatment with either oral capec...

journal_title：PharmacoEconomics

authors： Shiroiwa T,Fukuda T,Shimozuma K,Ohashi Y,Tsutani K

更新日期：2009-01-01 00:00:00

abstract：:As part of the National Institute for Health and Care Excellence's (NICE) Single Technology Appraisal (STA) process, ruxolitinib was assessed to determine the clinical and cost effectiveness of its use in the treatment of disease-related splenomegaly or symptoms in adults with myelofibrosis. Ruxolitinib had previously...

journal_title：PharmacoEconomics

authors： Wade R,Hodgson R,Biswas M,Harden M,Woolacott N

更新日期：2017-02-01 00:00:00

abstract：:Recombinant human erythropoietin (rHuEpo) has been increasingly used in preterm infants in the last 3 to 4 years. Recent studies have indicated a reduction in blood transfusion requirements in infants receiving rHuEpo. No significant adverse effects have emerged, apart from iron deficiency (if iron supplementation is ...

journal_title：PharmacoEconomics

authors： Meyer MP

更新日期：1997-10-01 00:00:00

abstract：BACKGROUND:Chronic obstructive pulmonary disease (COPD) is a progressive inflammatory lung disease associated with increasing morbidity and mortality and an economic burden that stretches beyond the patient to healthcare systems. Avoiding exacerbations and subsequent hospitalizations is an important clinical aim and ca...

journal_title：PharmacoEconomics

authors： Mittmann N,Hernandez P,Mellström C,Brannman L,Welte T

更新日期：2011-05-01 00:00:00

abstract：:The broad spectrum of antibacterial activity and favourable pharmacokinetic profile of ciprofloxacin permit oral treatment of many serious infections which have traditionally necessitated parenteral antibacterial therapy. This has been demonstrated in comparative studies, in which ciprofloxacin was as effective and w...

journal_title：PharmacoEconomics

authors： Balfour JA,Faulds D

更新日期：1993-05-01 00:00:00

abstract：:There is a global perspective to the economic consequences of diabetes, which is illustrated in the many publications now being produced on this subject. Because of the higher prevalence of type II diabetes, its impact is greater than that of type I diabetes in both developed and developing countries (but particularly...

journal_title：PharmacoEconomics

authors： Williams R

更新日期：1995-01-01 00:00:00

abstract：:The recent licensing of interferon-beta for use in patients with multiple sclerosis has caused concern, in view of the equivocal evidence of efficacy, pressure of public expectation towards its use and the high expected cost if widespread use were to be sanctioned. Whether such alarm is justified remains a moot point....

journal_title：PharmacoEconomics

authors： Tolley KH,Whynes DK

更新日期：1997-03-01 00:00:00

abstract：:Barrett's oesophagus is a premalignant complication that occurs in approximately 10% of patients with gastro-oesophageal reflux disease (GORD). In patients with Barrett's oesophagus, the risk of adenocarcinoma of the oesophagus approaches 0.5% per patient-years. Therefore, practice guidelines have been developed that ...

journal_title：PharmacoEconomics

authors： Arguedas MR,Eloubeidi MA

更新日期：2001-01-01 00:00:00

abstract：:We have defined the effect and acceptability of a locally developed general practice programme for the modification of prescribing. This voluntary programme consisted of prescription analysis and feedback, followed by visits from a pharmacist, a therapeutic bulletin on benzodiazepine prescribing, and use of a locally ...

journal_title：PharmacoEconomics

authors： Ferguson RI,Salmond CE,Maling TJ

更新日期：1995-06-01 00:00:00

abstract：:Diseases of the prostate currently represent a major health problem worldwide. As the age of the male population increases in the future, so will the number of patients suffering from these disorders and the cost for treatment increase. Currently, benign prostatic hyperplasia (BPH) and prostate cancer are common in ...

journal_title：PharmacoEconomics

authors： Amin EA,Amin M

更新日期：1992-05-01 00:00:00

abstract：BACKGROUND:Results from the PROVE IT trial suggest that patients with acute coronary syndrome (ACS) treated with atorvastatin 80 mg/day (A80) have significantly lower rates of cardiovascular events compared with patients treated with pravastatin 40 mg/day (P40). In a genetic post hoc substudy of the PROVE IT trial, the...

journal_title：PharmacoEconomics

authors： Parthan A,Leahy KJ,O'Sullivan AK,Iakoubova OA,Bare LA,Devlin JJ,Weinstein MC

更新日期：2013-06-01 00:00:00

abstract：:We review regulation of two important parameters for third-party payers and manufacturers of prescription drugs: regulation of reimbursement and pricing. We find that centralised regulation of reimbursement and pricing prevails in the 15 original EU member countries (EU-15) and in European Free Trade Association (EFTA...

journal_title：PharmacoEconomics

authors： Gress S,Niebuhr D,May U,Wasem J

更新日期：2007-01-01 00:00:00

abstract：BACKGROUND:Economic factors are a limiting factor toward the implementation of many health programmes and interventions. Economic evaluation has a great potential to contribute toward cost-effective healthcare delivery in South Africa. Little is known about the characteristics and quality of health economic (including ...

journal_title：PharmacoEconomics

authors： Gavaza P,Rascati KL,Oladapo AO,Khoza S

更新日期：2012-10-01 00:00:00

abstract：CONTEXT:This study assesses if, and how, existing methods for economic evaluation are applicable to the evaluation of personalized medicine (PM) and, if not, where extension to methods may be required. METHODS:A structured workshop was held with a predefined group of experts (n = 47), and was run using a modified nomi...

journal_title：PharmacoEconomics

authors： Rogowski W,Payne K,Schnell-Inderst P,Manca A,Rochau U,Jahn B,Alagoz O,Leidl R,Siebert U

更新日期：2015-01-01 00:00:00

abstract：:Several randomised comparative trials have shown that granulocyte colony-stimulating factor (G-CSF) reduces the duration of neutropenia, hospitalisation and intravenous antibacterial use in patients with cancer who are receiving high-dosage antineoplastic therapy. However, one area that has received less attention is ...

journal_title：PharmacoEconomics

authors： Dranitsaris G,Altmayer C,Quirt I

更新日期：1997-06-01 00:00:00

abstract：BACKGROUND:Economic models are considered to be important, as they help evaluate the long-term impact of diabetes treatment. To date, it appears that no article has reviewed and critically appraised the cost-effectiveness models developed to evaluate new oral treatments [glucagon-like peptide-1 (GLP-1) receptor agonist...

journal_title：PharmacoEconomics

authors： Asche CV,Hippler SE,Eurich DT

更新日期：2014-01-01 00:00:00

abstract：:Darunavir boosted by low-dose ritonavir (DRV/r), at a daily dose of 600/100 mg twice a day (bid), has been shown to be superior to alternative highly active antiretroviral therapy (HAART) regimens for the management of treatment-experienced, HIV-infected adults in the phase IIb POWER trials and the phase III TITAN tri...

journal_title：PharmacoEconomics

authors： Mauskopf J,Annemans L,Hill AM,Smets E

更新日期：2010-01-01 00:00:00

abstract：BACKGROUND:Several vaccine and antibody candidates are currently in development for the prevention of lower respiratory tract infections caused by the respiratory syncytial virus (RSV). METHODS:We searched MEDLINE, Embase, and SCOPUS and included model-based evaluations of RSV vaccinations. Two reviewers performed the...

journal_title：PharmacoEconomics

authors： Treskova M,Pozo-Martin F,Scholz S,Schönfeld V,Wichmann O,Harder T

更新日期：2021-01-19 00:00:00

abstract：:For practical reasons, in order to carry out economic evaluations of collective decisions, total costs will generally be compared with total benefits; hence, individuals' willingness to pay (WTP) or quality-adjusted life-years (QALYs) have to be estimated at an aggregate level. So far, aggregation has usually been don...

journal_title：PharmacoEconomics

authors： Liljas B,Lindgren B

更新日期：2001-01-01 00:00:00

abstract：BACKGROUND:In the past decade, the range of contraceptives available has increased dramatically. There are limited data on the factors that determine women's choices on contraceptive alternatives or what factors providers consider most important when recommending contraceptive products to women. OBJECTIVES:Our objecti...

journal_title：PharmacoEconomics

authors： Knox SA,Viney RC,Street DJ,Haas MR,Fiebig DG,Weisberg E,Bateson D

更新日期：2012-12-01 00:00:00

abstract：BACKGROUND:Carcinoid syndrome, a rare condition in patients with neuroendocrine tumours, characterised by flushing and diarrhoea, severely affects patients' quality of life. The current carcinoid syndrome standard of care includes somatostatin analogues, but some patients experience uncontrolled symptoms despite somato...

journal_title：PharmacoEconomics

authors： Fust K,Maschio M,Kohli M,Singh S,Pritchard DM,Marteau F,Myrenfors P,Feuilly M

更新日期：2020-06-01 00:00:00

abstract：:Whereas individual cost-effectiveness analyses of new agents for acute leukaemia should be performed in target populations, any meaningful pharmacoeconomic evaluation of treatment options for this condition should include the many types of costs and outcomes in unselected, representative groups of patients. Both direc...

journal_title：PharmacoEconomics

authors： Jønsson V,Hansen MM,Ljungman P,Kaasa S

更新日期：1999-02-01 00:00:00

abstract：BACKGROUND:The COUGAR-02 trial recently showed survival and quality-of-life benefits of docetaxel and active symptom control (DXL + ASC) over active symptom control (ASC) alone in patients with refractory oesophagogastric adenocarcinoma. AIM:The aim of this study was to conduct an economic evaluation conforming to Nat...

journal_title：PharmacoEconomics

authors： Meads DM,Marshall A,Hulme CT,Dunn JA,Ford HE

更新日期：2016-01-01 00:00:00